A-kinase anchoring protein (AKAP) inhibitors are a class of chemical compounds designed to specifically target and disrupt the function of AKAPs, which are a family of scaffold proteins that play a crucial role in the spatial and temporal regulation of cellular signaling. AKAPs facilitate the organization of signaling complexes by anchoring protein kinase A (PKA) and other signaling molecules to specific subcellular locations, such as the plasma membrane, mitochondria, or cytoskeleton. This localization ensures that PKA and its associated signaling partners are precisely positioned to respond to localized cAMP signals, thereby enabling targeted phosphorylation of substrates involved in processes like metabolism, gene expression, and cell motility. By inhibiting AKAPs, researchers can disrupt the assembly and localization of these signaling complexes, leading to altered signaling dynamics within the cell.
In research settings, AKAP inhibitors are valuable tools for studying the spatial regulation of signal transduction and the broader implications of compartmentalized signaling on cellular function. By blocking AKAP activity, scientists can investigate how the disruption of these scaffold proteins affects PKA signaling and the downstream pathways that depend on precise localization of signaling components. This inhibition allows researchers to explore the role of AKAPs in coordinating complex signaling events, such as those involved in cellular responses to hormonal stimulation, stress, and changes in the extracellular environment. Additionally, AKAP inhibitors enable the study of the interactions between AKAPs and other signaling molecules, providing insights into the molecular mechanisms that underlie the formation of signaling complexes and the regulation of their activity. Through these studies, the use of AKAP inhibitors enhances our understanding of the importance of spatial organization in cellular signaling, the role of scaffold proteins in maintaining signaling fidelity, and the broader consequences of disrupted signaling compartmentalization on cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $214.00 $316.00 $418.00 | 7 | |
5-Aza-2′-Deoxycytidine (Decitabine) could decrease AKAP9 expression by causing hypomethylation of its gene promoter, leading to transcriptional repression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
5-Aza-2′-Deoxycytidine (Vorinostat) may downregulate AKAP9 by increasing acetylation of histones near the AKAP9 gene, altering the chromatin structure to a state less conducive to gene expression. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
By inhibiting histone deacetylase activity, Trichostatin A may lead to hyperacetylated chromatin at the AKAP9 gene locus, resulting in decreased expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin (Sirolimus) could downregulate AKAP9 by inhibiting mTOR signaling, which is crucial for the transcriptional initiation of many genes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 may reduce AKAP9 expression by inhibiting the PI3K/Akt pathway, which is linked to the control of various cellular processes including gene expression. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
Fluorouracil could decrease AKAP9 expression by disrupting the synthesis of RNA, thereby hindering the transcription process of the AKAP9 gene. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid may downregulate AKAP9 by activating its nuclear receptors, which can bind to retinoic acid response elements in the promoters of target genes, including potentially AKAP9, leading to transcriptional repression. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate could inhibit AKAP9 expression by interfering with folate metabolism, which is essential for the synthesis of nucleotides and hence for gene transcription. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Hydroxyurea might reduce AKAP9 expression levels by inhibiting ribonucleotide reductase, which is necessary for DNA synthesis and subsequent gene transcription processes. | ||||||
Ellagic Acid, Dihydrate | 476-66-4 | sc-202598 sc-202598A sc-202598B sc-202598C | 500 mg 5 g 25 g 100 g | $57.00 $93.00 $240.00 $713.00 | 8 | |
Ellagic acid may downregulate AKAP9 by inhibiting the DNA-binding activity of NF-kB, which can suppress the transcription of certain genes, potentially including AKAP9. | ||||||